Does Serum CA19-9 Play a Practical Role in the Management of Patients with Colorectal Cancer?

Diseases of the Colon and Rectum

Volumn 47, Issue 2, 2004, Pages 227-232

  Morita, Shunji ^a   Nomura, Takashi ^a   Fukushima, Yukio ^a   Morimoto, Takashi ^a   Hiraoka, Nobuaki ^a   Shibata, Nobuhiro ^a  

^a Yao Municipal Hospital   (Japan)

Author keywords

CA19 9; Carcinoembryonic antigen; Colorectal cancer; Prognosis; Recurrence; Screening; Surveillance

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SERUM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0842348755     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-003-0041-6     Document Type: Article

References (25)

1. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
2. Vernava AM, Longo WE, Virgo KS, Coplin MA, Wade TP, Johnson FE. Current follow-up strategies after resection of colon cancer: results of a survey of members of The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1994;37:573-83.
3. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998;228:59-63.
4. Sugarbaker PH, Gianola FJ, Dwyer A, Neuman NR. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987;102:79-87.
5. Filella X, Molina R, Grau JJ, et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 1992;216:55-9.
6. Diez M, Cerdan FJ, Pollan M, et al. Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma. Anticancer Res 1994;14:2819-25.
7. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000;20:5195-8.
8. Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology 1999;46:905-8.
9. Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers. Surg Today 1994;24:518-25.
10. Franchi F, Pastore C, Izzo P, Calio E. Ca 19-9 in the monitoring of colorectal cancer after surgery. Med Oncol 2001;18:237-8.
11. Sears HF, Herlyn M, Del Villano B, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol 1982;2:141-9.
12. Nicolini A, Caciagli M, Zampieri F, et al. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the diagnosis of primary colorectal cancer and at its relapse. Cancer Detect Prev 1995;19:183-95.
13. Nakayama T, Watanabe M, Teramoto T, Kitajima M. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Anticancer Res 1997;17:1379-82.
14. Holubec L, Topolcan O, Pikner R, et al. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. Anticancer Res 2000;20:5237-44.
15. Spila A, Ferroni P, Cosimelli M, et al. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation. Anticancer Res 2001;21:1263-70.
16. Filella X, Molina R, Pique JM, et al. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumour Biol 1994;15:1-6.
17. Griesenberg D, Nurnberg R, Bahlo M, Klapdor R. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Res 1999;19:2443-50.
18. Plebani M, De Paoli M, Basso D, et al. Serum tumor markers in colorectal cancer staging, grading, and follow-up. J Surg Oncol 1996;62:239-44.
19. Novis BH, Gluck E, Thomas P, et al. Serial levels of CA 19-9 and CEA in colonic cancer. J Clin Oncol 1986;4:987-93.
20. Szymendera JJ, Nowacki MP, Kozlowicz-Gudzinska I, Kowalska M. Value of serum levels of carcinoembryonic antigen, CEA, and gastrointestinal cancer antigen, GICA or CA 19-9, for preoperative staging and postoperative monitoring of patients with colorectal carcinoma. Dis Colon Rectum 1985;28:895-9.
21. Sato T, Nishimura G, Nonomura A, Miwa K, Miyazaki I. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer. Hepatogastroenterology 1999;46:914-9.
22. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998;114:7-14.
23. Wanebo HJ, Llaneras M, Martin T, Kaiser D. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet 1989;169:479-87.
24. Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985;55:1284-90.
25. Hanke B, Riedel C, Lampert S, et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 2001;12:221-6.